CERS2

Across TCGA pan-cancer cohorts, CERS2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CERS2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CERS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CERS2 expression acts as an unfavorable survival marker.

KIRC, UCEC, and STAD are the cancer types where CERS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.123	0.805	<.001	42	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	All	0.267	0.729	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CERS2–KIRC (OS)

Open the KIRC breakdown →